Is SGMT or CYPH more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -31.96% -30.57% Cypherpunk Technologies N/A -20.76% -19.48%

Does the media refer more to SGMT or CYPH?

In the previous week, Sagimet Biosciences and Sagimet Biosciences both had 8 articles in the media. Sagimet Biosciences' average media sentiment score of 0.74 beat Cypherpunk Technologies' score of 0.48 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cypherpunk Technologies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CYPH or CBIO more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -20.76% -19.48% Crescent Biopharma N/A -101.50% -86.86%

Does the media prefer CYPH or CBIO?

In the previous week, Crescent Biopharma had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 9 mentions for Crescent Biopharma and 8 mentions for Cypherpunk Technologies. Crescent Biopharma's average media sentiment score of 0.56 beat Cypherpunk Technologies' score of 0.48 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VSTM or CYPH?

In the previous week, Cypherpunk Technologies had 5 more articles in the media than Verastem. MarketBeat recorded 8 mentions for Cypherpunk Technologies and 3 mentions for Verastem. Verastem's average media sentiment score of 1.08 beat Cypherpunk Technologies' score of 0.48 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cypherpunk Technologies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRME or CYPH?

In the previous week, Prime Medicine and Prime Medicine both had 8 articles in the media. Prime Medicine's average media sentiment score of 0.82 beat Cypherpunk Technologies' score of 0.48 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cypherpunk Technologies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, EIKN or CYPH?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A Cypherpunk Technologies N/A N/A $4.82M $0.56 3.05

Is EIKN or CYPH more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Cypherpunk Technologies N/A -20.76% -19.48%

Does the media refer more to EIKN or CYPH?

In the previous week, Cypherpunk Technologies had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 8 mentions for Cypherpunk Technologies and 5 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.91 beat Cypherpunk Technologies' score of 0.48 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cypherpunk Technologies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Cypherpunk Technologies (CYPH) Competitors

$1.71 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

CYPH vs. SGMT, CBIO, VSTM, PRME, and EIKN

Should you buy Cypherpunk Technologies stock or one of its competitors? Cypherpunk Technologies's main competitors and comparable companies include Sagimet Biosciences (SGMT), Crescent Biopharma (CBIO), Verastem (VSTM), Prime Medicine (PRME), and Eikon Therapeutics (EIKN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cypherpunk Technologies compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Sagimet Biosciences has a beta of 3.37, suggesting that its stock price is 237% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Cypherpunk Technologies has lower revenue, but higher earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	327.89	-$51.04M	-$1.28	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	3.05

In the previous week, Sagimet Biosciences and Sagimet Biosciences both had 8 articles in the media. Sagimet Biosciences' average media sentiment score of 0.74 beat Cypherpunk Technologies' score of 0.48 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cypherpunk Technologies	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cypherpunk Technologies' return on equity of -20.76% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

Sagimet Biosciences currently has a consensus target price of $29.17, indicating a potential upside of 176.46%. Cypherpunk Technologies has a consensus target price of $1.60, indicating a potential downside of 6.43%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Sagimet Biosciences is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sagimet Biosciences beats Cypherpunk Technologies on 8 of the 13 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Crescent Biopharma?

Cypherpunk Technologies (NASDAQ:CYPH) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Crescent Biopharma had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 9 mentions for Crescent Biopharma and 8 mentions for Cypherpunk Technologies. Crescent Biopharma's average media sentiment score of 0.56 beat Cypherpunk Technologies' score of 0.48 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cypherpunk Technologies currently has a consensus price target of $1.60, suggesting a potential downside of 6.43%. Crescent Biopharma has a consensus price target of $29.60, suggesting a potential upside of 66.76%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Crescent Biopharma is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Cypherpunk Technologies has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Cypherpunk Technologies has higher earnings, but lower revenue than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	3.05
Crescent Biopharma	$10.84M	60.82	-$153.94M	-$6.72	N/A

Cypherpunk Technologies' return on equity of -20.76% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-20.76%	-19.48%
Crescent Biopharma	N/A	-101.50%	-86.86%

Summary

Crescent Biopharma beats Cypherpunk Technologies on 10 of the 15 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Verastem?

Verastem (NASDAQ:VSTM) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

In the previous week, Cypherpunk Technologies had 5 more articles in the media than Verastem. MarketBeat recorded 8 mentions for Cypherpunk Technologies and 3 mentions for Verastem. Verastem's average media sentiment score of 1.08 beat Cypherpunk Technologies' score of 0.48 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cypherpunk Technologies	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verastem has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Verastem presently has a consensus price target of $13.83, indicating a potential upside of 91.60%. Cypherpunk Technologies has a consensus price target of $1.60, indicating a potential downside of 6.43%. Given Verastem's stronger consensus rating and higher probable upside, analysts plainly believe Verastem is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cypherpunk Technologies has lower revenue, but higher earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	21.15	-$209.47M	-$2.66	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	3.05

Cypherpunk Technologies has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Cypherpunk Technologies' return on equity of -20.76% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

88.4% of Verastem shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Verastem and Cypherpunk Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Prime Medicine currently has a consensus target price of $7.47, indicating a potential upside of 106.99%. Cypherpunk Technologies has a consensus target price of $1.60, indicating a potential downside of 6.43%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Prime Medicine is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Prime Medicine and Prime Medicine both had 8 articles in the media. Prime Medicine's average media sentiment score of 0.82 beat Cypherpunk Technologies' score of 0.48 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cypherpunk Technologies	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Cypherpunk Technologies has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Cypherpunk Technologies' return on equity of -20.76% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cypherpunk Technologies has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.07M	160.76	-$201.14M	-$1.06	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	3.05

Summary

Prime Medicine beats Cypherpunk Technologies on 9 of the 15 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Eikon Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 127.69%. Cypherpunk Technologies has a consensus price target of $1.60, indicating a potential downside of 6.43%. Given Eikon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Eikon Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eikon Therapeutics' return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Cypherpunk Technologies	N/A	-20.76%	-19.48%

30.5% of Cypherpunk Technologies shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	3.05

In the previous week, Cypherpunk Technologies had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 8 mentions for Cypherpunk Technologies and 5 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.91 beat Cypherpunk Technologies' score of 0.48 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cypherpunk Technologies	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eikon Therapeutics and Cypherpunk Technologies tied by winning 6 of the 12 factors compared between the two stocks.

Get Cypherpunk Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYPH vs. The Competition

Export

Metric	Cypherpunk Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$184.27M	$3.94B	$7.18B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	3.05	11.68	273.17	25.45
Price / Sales	N/A	1,408.89	638.21	103.75
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.93	16.92	11.08	6.36
Net Income	$4.82M	-$22.74M	$3.48B	$349.79M
7 Day Performance	1.79%	-0.13%	0.38%	-0.40%
1 Month Performance	189.54%	11.45%	7.89%	4.24%
1 Year Performance	492.93%	55.66%	24.71%	15.13%

Cypherpunk Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYPH Cypherpunk Technologies	1.8705 of 5 stars	$1.71 flat	$1.60 -6.4%	+492.9%	$184.27M	N/A	3.05	40	Gap Up
SGMT Sagimet Biosciences	3.25 of 5 stars	$10.75 -1.0%	$29.17 +171.3%	+40.5%	$675.04M	$2M	N/A	8
CBIO Crescent Biopharma	2.7992 of 5 stars	$17.76 -1.4%	$29.60 +66.7%	+23.3%	$669.33M	$10.84M	N/A	50	Positive News
VSTM Verastem	3.2171 of 5 stars	$7.38 -0.1%	$13.83 +87.4%	-21.9%	$669.26M	$87.53M	N/A	50	Positive News
PRME Prime Medicine	2.7423 of 5 stars	$3.64 +1.7%	$7.47 +105.3%	N/A	$649.33M	$4.07M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYPH) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. SGMT, CBIO, VSTM, PRME, and EIKN

How does Cypherpunk Technologies compare to Sagimet Biosciences?

Summary

How does Cypherpunk Technologies compare to Crescent Biopharma?

Summary

How does Cypherpunk Technologies compare to Verastem?

Summary

How does Cypherpunk Technologies compare to Prime Medicine?

Summary

How does Cypherpunk Technologies compare to Eikon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. SGMT, CBIO, VSTM, PRME, and EIKN

How does Cypherpunk Technologies compare to Sagimet Biosciences?

Which has more risk and volatility, SGMT or CYPH?

Which has higher valuation and earnings, SGMT or CYPH?

Does the media refer more to SGMT or CYPH?

Do institutionals and insiders believe in SGMT or CYPH?

Is SGMT or CYPH more profitable?

Do analysts rate SGMT or CYPH?

Summary

How does Cypherpunk Technologies compare to Crescent Biopharma?

Do insiders & institutionals hold more shares of CYPH or CBIO?

Does the media prefer CYPH or CBIO?

Do analysts recommend CYPH or CBIO?

Which has more risk & volatility, CYPH or CBIO?

Which has preferable earnings and valuation, CYPH or CBIO?

Is CYPH or CBIO more profitable?

Summary

How does Cypherpunk Technologies compare to Verastem?

Does the media refer more to VSTM or CYPH?

Which has more volatility and risk, VSTM or CYPH?

Do analysts rate VSTM or CYPH?

Which has stronger earnings and valuation, VSTM or CYPH?

Is VSTM or CYPH more profitable?

Do insiders and institutionals have more ownership in VSTM or CYPH?

Summary

How does Cypherpunk Technologies compare to Prime Medicine?

Do analysts recommend PRME or CYPH?

Does the media favor PRME or CYPH?

Which has more volatility and risk, PRME or CYPH?

Is PRME or CYPH more profitable?

Do institutionals & insiders believe in PRME or CYPH?

Which has stronger valuation & earnings, PRME or CYPH?

Summary

How does Cypherpunk Technologies compare to Eikon Therapeutics?

Do analysts recommend EIKN or CYPH?

Is EIKN or CYPH more profitable?

Do institutionals and insiders believe in EIKN or CYPH?

Which has better earnings and valuation, EIKN or CYPH?

Does the media refer more to EIKN or CYPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools